[Seite 59↓]

LITERATURVERZEICHNIS

1 Klopp C.T.,Alford T.C., Bateman J.: ractional intra-arterial cancer chemotherapy with methyl-bis-amine hydrochloride. Ann Surg. 1950, Bd. 132, S.811-832,

2 Sullivan R.F., Jones R., Schnabel T.G., Shorey J.M.: The treatment of human cancer with intra-arterial nitrogen mustard utilizing a simplified catheter technique. Cancer. 1953, Bd. 6, S.121-134,

3 Ryan R.F., Krementz E.T., Creech O., Winblad J.N., Chamblee W., Cheek H. : Selected perfusion of isolated viscera with chemotherapeutic agents using extracorporal circuit. Surg Forum. 1957, Bd. 8, S.158-161,

4 Creech O., Krementz E.T., Ryan R.F., Winblad J.N.: Chemotherapy of cancer: regional perfusion utilizing an extracorporal circuit. Ann Surg. 1958, Bd. 148, S.616-631,

5 Cavaliere R., Ciocatto E.C., Giovanella B.C., Heidelberger C., Johnson R.O., Margottini M. et al.: Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer. 1967, Bd. 20, S.1351-1381,

6 Stehlin J.S., Giovanella B.C., Delpolyi P.D., Muenz L.R., Anderson R.F.: Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet. 1975, Bd. 140, S.339-348,

7 Eggermont A.M., Schraffordt Koops H., Klausner J.M., Kroon B.B., Schlag P.M., Lienard D. et al: Isolated limb perfusion with tumor nekrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg. 1996, Vol 224, No 6, S.756-765,

8 Thompson J.F., Hunt J.A., Shannon K.F., Kam P.C.: Frequency and duration of remission after isolated limb perfusion for melanoma. Archives of Surgery. 1997, Vol 132, No 8, S.903-907,

9 Lienard D., Ewalenko P., Delmotte J.J., Lejeune F.J. : High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992, Vol. 10, S.52-60,

10 Lienard D., Eggermont A.M., Schrafford Koops H., Kroon B.B., Rosenkaimer F., Autier P. et al : Isolated perfusion of the limb with high-dose tumor necrosis factor alpha, interferon-gamma and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res. 1994, Vol. 4, S1, S.21-26,

11 Frater-Schröder M., Risau W., Hallmann R., Gautschi P., Böhlen P. : Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA. 1987, Vol. 84, S.5277-5281,


[Seite innerhalb Literaturhinweis 60↓]

12 Sato N., Goto T., Haranaka K., Satomi N., Nariuchi H., Mano-Hirano Y. et al: Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inibation, and cytotoxity. J Natl Cancer Inst. 1986, Vol. 76, S.1113-1121,

13 Stolpen A.H., Guinan E.C., Fiers W., Pober J.S.: Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganze human vascular endothelial cell monolayers. Am J Pathol. 1986, Vol. 23, S.16-24,

14 Kettelhack C., Robaye B., Morandini R., Mosselmans R., Ghanem G., Lejeune F.: Induction of apoptosis in human endothelial cells by TNF and interferon-gamma. Annals of Hematology 67. 1993, S.156,

15 Pober J.S., Cotran R.S.: Cytokines and endothelial cell bioogy. Physio Rev. 1990, Vol. 70, S.427-451,

16 Lejeune F., Lienard D., Eggermont A., Schrafford Koops H., Rosenkaimer F., Gerain J. : Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem. 1994, Vol.56, S.52-61,

17 Olieman A.F., van-Ginkel R.J., Hoekstra H-J., Mooyaart E.L., Molenaar W.M., Koops H.S.: Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol. 1997, Vol. 4, No 1, S.64-69,

18 Bone R.C.: ACCP/SCCM consensus conference: Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992, Vol 20, S.864-874,

19 Sablotzki A., Dehne M., Welters I. et al.: Alterations of the cytokine network in patients undergoing cardiopulmonary bypass. Perfusion. 1997, 12, S.393-403,

20 Nathan N., Denizot Y., Cornu E. et al.: Cytokine and lipid mediator blood concentrations after coronary artery surgery. Anesth Analg. 1997, 85, S.1240-1246,

21 Toft P., Tonnesen E., Zülow I. et al.: Expression of adhesion and activation molecules on lymphocytes during open-heart surgery with cardiopulmonary bypass. Scand Cardiovasc J. 1997, 31, S.91-95,

22 Hensel M., Volk T., Döcke W.D. et al.: Hyperprocalcitoninemia in patients with noninfectious SIRS and pulmonary dysfunction associated with cardiopulmonary bypass. Anesthesiology. 1998, 89, S.93-104,

23 Zwaveling J.H., Maring J.K., Clarke F.L., van Ginkel R.J., Hoekstra H.J.: High plasma tumor necrosis factor concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF- alpha, interferon-gamma and melphalan. Critical Care Med. 1996, Vol. 24, No 5, S.765-770,


[Seite innerhalb Literaturhinweis 61↓]

24 Zwaveling J.H., Maring J.K., Moshage H., van Ginkel R.J., Hoekstra H.J., Schrafford Koops H. et al: Role of nitric oxide in recombinant tumor necrosis factor alpha induced circulatory shock: a study in patients treated for cancer with isolated limb perfusion. Critical Care Med. 1996, Vol. 24, No 11, S.1806-1810,

25 Fawcett W.J., Hill S., Sheldon J., Williams T.R., Thomas J.M., Riches P.: Hemodynamic changes and circulating recombinant tumor necrosis factor-alpha concentrations in a patient undergoing isolated limb perfusion. Critical Care Med. 1993, Vol. 21, S.796-800,

26 Sigurdsson G.H., Nachbur B., Lejeune F.J.: Anesthesoilogists` Management of Isolated Limb Perfusion with High-dose Tumor Necrosis Factor alpha. Anesthesiology. 1993, 79, S.1433-1437,

27 Lejeune F.J., Lienard D., Eggermont A.M. et al.: Isolation perfusion with rTNFalpha, rINFgamma + melphalan for in transit metastases of malignant melanoma. Update of a pilot study. European Journal of Cancer. 1993, 29, S.117,

28 Vaglini M., Belli F., Ammatuna M. et al.: Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor nekrosis factor, gamma-interferon and melphalan. Cancer. 1994, 73, S.483-492,

29 Fraker D.L., Alexander H.R., Andrich M.P., Rosenberg S.A.: Treatment of patients with melanom of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996, 14, S.479-489,

30 Wieberdink J., Benckhuysen C., Braat R.P., Van Slooten E.A., Olthuis G.A. : Dosimetry in isolation perfusion of the limbs by assessement of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1986, S.1819-1826,

31 Eggimann P., Chiolero R., Chassot P.-G. et al: Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest. 1995, 107, S.1074-1082,

32 Goris R.J.A.: MODS/SIRS: result of an owerhelming inflammatory response?. World J Surg. 1996, 20, S.418-421,

33 Nathens A.B., Marshall J.C.: Sepsis, SIRS and MODS: what's in a name?. World J Surg. 1996, 20, S.386-391,

34 Ganz W., Swan H.J.C.: Measurement of Blood Flow by Thermodilution. American Journal of Cardiolgy. 1972, Vol. 29, S.241-245,


[Seite innerhalb Literaturhinweis 62↓]

35 Assman R., Heidelmeyer C.F., Trampisch H.J., Mottaghy K.,Verprille A., Sandmann W., Falke K.J.: Right ventricular function assessed by thermodilution technique during apnea and mechanical ventilation. Crit Care Med. 1991, 6, S.810-817,

36 Yelderman M.: Continuous cardiac Output by thermodilution. Int Anaesthesiol Clin. 1993, Vol. 31, No. 3 , S.127-140,

37 Jacquet L., Hanique G., Glrieux D., Matte P., Goenen M.: Analysis of the accuracy of continuous thermodilution cardiac output measurement. Comparision with intermittent thermodilution and Fick cardiac output measurement. Intensive Care Medicine. 1996, Vol. 22, S.1125-1129,

38 Fick A.: Über die Messung des Blutquantums in den Herzventrikeln. Sitzungsbericht der Physikalisch Medizinischen Gesellschaft Würzburg. 1870, S.16f,

39 Weyland A.,Weyland W., Sydow M., Weyland C., Kettler D.: Inverses Ficksches Prinzip im Vergleich zu Messungen der Sauerstoffaufnahme aus respiratorischen Gasen. Anaesthesist. 1994, S.658-666,

40 Thews G: Lungenatmung. Hrsg.: Schmidt R.F., Thews G.: Physiologie des Menschen. Band 1. 26 Berlin, Heidelberg, New York, Springer Verlag, 1995 S.565-590,

41 Wells J.C.K., Fuller N.J.: Precision and accuracy in a metabolic monitor for indirect calorimetry. European Journal of Clinical Nutrition. 1998, Vol. 52, S.536-540,

42 Scheeren T.W.L., Krossa M., Meriläinen P., Arndt J.O.: Error in measurement of oxygen cabon dioxide concentration by the Deltatrac II metabolic monitor in the presence of desflurane. British Journal of Anaesthesia. 1998, Vol. 80, S.521-524,

43 Bland J.M., Altman D.G.: Statistical methods for assesing agreement between two methods of clinical measurement. Lancet. 1986, 2, S.307-310,

44 Nunn J.F.: Pulmonary oxygen consumption. Intensive Care Med. 1996, 22, S.275-276,

45 Light R.B.: Intrapulmonary oxygen consumption in experimental pneumococcal pneumonia. J Appl Physiol. 1988, Vol. 64, S.2490-2495,

46 Omlor G., Molter G., Meessen S., Gross G., Seyfert U., Feifel G.: Kardiozirkulatorische Nebenwirkungen der hyperthermen Extremitätenperfusion. Langenbecks Arch Chir. 1993, 378, S.17-20,

47 Harpole D.H., Clements F.M., Quill T., Wolfe W.G.: Right and left ventricular performance during and after abdominal aortic aneurysm repair. Ann Surg. 1989, 209, S.356-362,


[Seite innerhalb Literaturhinweis 63↓]

48 Nunn J.F.: Non respiratory functions of the lung. Hrsg.: Nunn J.F.: Applied respiratory physiology. Band 1. 4 London, Boston, Butterworth-Heinemann, 1993 S.306-317,

49 Hensel M., Kox W.J.: Increased Intrapulmonary Oxygen Consumption in Mechanically Ventilated Patients with Pneumonia. Am J Respir Crit Care Med. 1999, 160, S.137-143,

50 Shomaker W.C., Montgomery E.S., Kaplan E. et al: Physiologic patterns in surviving and nonsurviving shock patients. Arch Surg. 1973, 106, S.630 ff,

51 Royston D.: Systemic inflammatory responses to surgery whith cardiopulmonary bypass. Perfusion. 1996, 11, S.177-189,

52 Gosh S., Latimer R.D., Gray B.M., Harwood R.J., Oduro A: Endotoxin induced organ injury. Crit Care Med. 1993, Vol 21, S.19-24,

53 Gerain J., Lienard D., Ewalenko P., Lejeune F.J. : High serum levels of TNF-alpha after its administration for isolation of the limb. Cytokine. 1992, Vol. 4, S.585-591,

54 Thom A.K., Alexander H.R., Andrich M.P., Barker W.C., Rosenberg S.A., Fraker D.L. : Cytokine levels and systemic toxity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon-gamma and melphalan. J Clin Oncol . 1995, Vol. 13, S.264-273,

55 Sorkin P., Abu-Abid S., Lev D., Gutman M., Aderka D., Halpern P. et al: Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg. 1995, Vol. 130, S.1079-1084,

56 Menasche P., Haydar S., Peynet J., Du Buit C., Merval R., Bloch G., Pivnica A.: A potential mechanism of vasodilatation after warm heart surgery: the temperature dependent release of cytokines. J Thorac Cardiovasc Surg. 1994, 107, S.293-299,

57 Butler J., Rocker G.M., Westaby S.: Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993, Vol.55, S.552-559,

58 Chenoveth D.E., Cooper S.W., Hugli T.E., Stewart R.W., Blackstone E.H., Kirklin J.W. : Complement activation during cardiopulmonary bypass. N Engl J Med. 1981, Vol 304, S.497, 503.

59 Cremer J., Martin M., Redl H., Bahrami S., Abraham C., Graeter T., Haverich A., Schlag G., Borst H.G. : Systemic inflammatoric response syndrom after cardiac operations. Ann Thorac Surg. 1996, Vol. 61, S.1714-1720,

60 Gillinov A.M., Bator J.M., Zehr K.J., Redmond J.M., Burch R.M., Ko C., Winkelstein J.A., Stuart R.S., Baumgartner W.A., Cameron D.E.: Neutrophil adhesion molecule expression during cardiopulmonary bypass whith bubble and membran oxygenators. Ann Thorac Surg. 1993, Vol.56, S.847-853,


[Seite innerhalb Literaturhinweis 64↓]

61 Menasche P.: The inflamatory response to cardiopulmonary bypass and its impact on postoperative myocardialfunktion. Curr Opin Caardiol. 1995, 10, S.597-604,

62 Lehmann A., Zeitler C., Thaler E. et al.: Comparison of two different anesthesia regimes in patients undergoing aortocoronary bypass grafting surgery: sufentail-midazolam versus remifentanil-propofol. J Cardiothorac Vasc Anesth. 2000, 4, S.416-420,

63 Hogue C.W., Browdle T.A., O'Leary C. et al.: A multicenter evaluation of total intravenous anesthesia with remifentanil and propofol for elective inpatient surgery. Anesth Analg. 1996, Vol 83, S.279-285,

64 Neuhof H., Wolf H.: Method for continuosly measured oxygen consumption and cardiac output for use in critically ill patients. Crit Care Med. 1978, Vol.6, S.155-161,

65 Connors A. F., Speroff T., Dawson N.V., Thomas C., Harrel F.E. et al.: The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA. 1996, 276, S.889-897,

66 Third European Consensus Conference in Intensive Care Medicine. Tissue hypoxia: How to detect, how to correct, how to prevent. Societe de Reanimacion de Langue Francaise. The American Thoracic Society. European Society of Intensive Care Medicine. Am J Respir Crit Care Med. 1996, Vol. 154, S.1573-1578,

67 Pulmonary artery catheter consensus conference: Consensus statement. Crit Care Med. 1997, S.910-925,

68 Parker M.M., Peruzzi W.: Pulmonary artery catheters in sepsis/septic shock. New Horiz. 1997, S.228-232,

69 Nunn J.F., Makita K., Royston B.: Validation of oxagen consumption measurements during artificial ventilation. J Appl Physiol.. 1989, Vol. 67, S.2129-2134,

70 Loer S.A., Scheeren T.W., Tarnow J.: How much oxygen does the human lung consume?. Anesthesiology. 1997, S.532-637,

71 Douglas C.G., Haldane J.S.: The regulation of the general circulation rate in man. J Physiol. 1922, Vol.56, S.69-100,

72 Scheeren T.W.L., Schwarte L.A., Arndt J.O.: Metabolic regulation of cardiac output during inhalation anaesthesia in dogs. Acta Anaesthesiol Scand. 1999, Vol. 43, S.421-423,

73 Scheeren T. W.: Beziehung zwischen Herzminutenvolumen und Sauerstoffverbrauch bei Inhalationsanästhesien und unter dem Einfluß von Katecholaminen. Anaesthesiol Intensivmed-Notfallmed-Schmerzther. 2000, Bd. 35 , S.214-219,


[Seite innerhalb Literaturhinweis 65↓]

74 Bihari D., Smithies M., Gimson A., Tinker J.: The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients. N Engl J Med. 1987, 317, S.397-403,

75 Hayes M.A., Timmins A.C., Yau E.H., Palazzo M., Watson D., Hinds C.J.: Oxygen transport patterns in patients with sepsis syndrom or septic shock: influence of treatment and relationship to outcome. Crit Care Med. 1997, S.926-936,

76 Rhodes A., Malagon I., Lamb F.J., Newman P., Grounds R.M., Bennett E.D.: Failure to increase oxygen consumption is a predictor of mortality in septic patients. Intensiv Care Med. 1996, Vol. 22, S.274ff,

77 Archie J.: Mathematic Coupling of Data. Ann. Surg. 1981, Vol.193, No. 3, S.296-303,

78 Ronco J.J., Fenwick J.C., Tweeddale .G. et al.: Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and nonseptic humans. JAMA. 1993, 270, S.1724-1730,

79 Wysocki M., Besbes M., Roupie E. et al.: Modification of oxygen extraction ratio by change in oxygen transport in septic shock. Chest. 1992, 102, S.221.226,

80 Vermej C.G., Feenstra B.W., Adrichem W.J., Bruining H.A.: Independent oxygen uptake and oxygen delivery in septic and postoperative patients. Chest. 1991, 99, S.1438-1441,

81 Friedman G., de Backer D., Shala M., Vincent J.L.: Oxygen supply depency can characterize septic shock. Intensive Care Med. 1998, 24, S.118-123,

82 de Boisblanc B.P.: Oxygen consumption in the intensive care unit: Indirect calorimetry is the way to go, but where?. Crit Care Med. 1998, Vol. 26 No. 7, S.1153-1154


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
XDiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
16.06.2005